2 news items
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REPL
23 May 24
. As previously disclosed, the topline 12-month primary analysis results by independent central review are expected later in Q2 2024
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
REPL
16 May 24
analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma expected
- Prev
- 1
- Next